

February 10, 2024

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1
G Block, Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Dept. of Listing Operations
BSE Limited,
P J Towers, Dalal Street,
Mumbai -400001, India

Symbol: YATHARTH

Scrip Code: 543950

Sub: Outcome of Board Meeting for Quarterly Financial Results.

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

In continuation to our earlier letter dated February 02, 2024, we wish to inform that the board of directors ("Board") of the Company at their meeting held today i.e. February 10, 2024, inter-alia, have approved unaudited standalone & consolidated financial results ("Financial Results") of the Company for quarter ended December 31, 2023, based on the recommendation of Audit Committee.

Financial Results together with respective limited review reports issued by R. Nagpal Associates, chartered accountants, statutory auditors of the Company are enclosed as Annexure.

The Board meeting commenced at 04.00 PM (IST) and concluded at 6:34 PM (IST).

This disclosure will also be hosted on Company's website viz. www.yatharthhospitals.com/

Kindly take the same on record.

Thanking you,

Your faithfully,
For Yatharth Hospital and Trauma Care Services Limited



Ritesh Mishra
Company Secretary & Compliance Officer
Mem. No. A51166
Enclosed: As above

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi - 110025
Tel: 011-49967892

Our Hospitals

📍 Sector 110, Noida, Uttar Pradesh-201304
📍 Sector Omega -01, Greater Noida, Uttar Pradesh-201308



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Holding Company) and its subsidiaries (The Holding Company and its Subsidiaries together referred to as 'the Group') for the quarter ended December 31, 2023 and year to date from April 1, 2023 to December 31, 2023 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of



persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulation, to the extent applicable.

4. The Statement includes the results of the following Subsidiaries:


- (i) AKS Medical & Research Centre Private Limited
- (ii) Ramraja Multispeciality Hospital & Trauma Centre Private Limited
- (iii) Sanskar Medica India Limited

5. Other Matters

We did not review the financial results of Three subsidiaries included in the consolidated financial results whose financial results reflect Total revenues of Rs. 652.77 Millions, and Rs. 1785.97 Millions for the quarter and year to date ended 31st December, 2023 respectively, total Net Profit after tax of Rs.83.85 Millions and Rs.183.72 Millions for the quarter and year to date ended 31st Dec 2023 respectively and total comprehensive income of Rs. 83.85 Millions and Rs. 183.72 Millions for the quarter and year to date ended 31st December, 2023 respectively, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.


Our Conclusion on above matter is not modified.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information



required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

For R. Nagpal Associates
Chartered Accountants
Firm Registration No. 002626N


(CA. Rohit Mehra)

Partner

Membership No. 093910



UDIN: 24093910 BKAKCH2020

Place: Noida

Date: 10th February 2024

YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: www.yatharthhospitals.com

Email: ca@yatharthhospitals.com

CIN : U85110DL2008PLC174706

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTH ENDED 31TH DECEMBER, 2023

Rs. in Million except Shares and EPS

Particulars	Consolidated					
	Quarter Ended			Nine Month Ended		Year Ended
	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue from operations	1,667.93	1,712.80	1,375.45	4,925.80	3,765.01	5,202.93
II Other income	53.77	38.21	8.00	99.54	21.30	28.07
III Total Income (I+II)	1,721.70	1,751.00	1,383.45	5,025.34	3,786.31	5,231.00
IV Expenses						
Medical consumables and pharmacy items consumed	315.22	360.47	227.98	956.21	671.88	929.35
Employee benefits expense	299.25	283.93	236.20	851.56	668.90	919.30
Finance costs	1.67	29.41	59.62	90.38	154.38	213.87
Depreciation and amortisation	78.52	68.79	68.98	216.04	192.47	275.07
Other expenses	589.22	612.70	550.42	1,783.95	1,471.31	2,016.63
Total expenses (IV)	1,283.88	1,355.30	1,143.20	3,898.13	3,158.94	4,354.22
V Profit / (loss) before exceptional items and tax (III-IV)	437.82	395.70	240.25	1,127.21	627.37	876.78
VI Exceptional items (net)(Gain)/Loss	-	-	-	-	-	-
VII Profit / (loss) before tax (V-VI)	437.82	395.70	240.25	1,127.21	627.37	876.78
VIII Tax expense						
(1) Current tax	140.38	116.91	44.35	359.88	174.61	246.65
(2) MAT credit entitlement	-	-	-	-	1.15	1.61
(2) Income tax of earlier years	-	-	-	-	-	11.02
(3) Reversal of MAT credit entitlement of earlier years	-	4.88	-	4.88	-	-
(4) Deferred tax	2.57	(2.11)	(16.64)	1.19	(32.88)	(40.19)
Total tax (VIII)	142.94	119.68	27.71	365.94	142.88	219.10
IX Net Profit/(loss) after tax (VII-VIII)	294.88	276.03	212.54	761.26	484.49	657.68
X Other Comprehensive Income						
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	3.91	-	4.17	4.01
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(0.87)	-	(0.93)	(0.90)
Other comprehensive income for the period	-	-	3.04	-	3.24	3.11
XI Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)	294.88	276.03	215.58	761.26	487.73	660.80
Profit/(Loss) for the year attributable to:						
To the Owners of the company	294.88	276.03	212.54	761.26	484.49	657.68
Non Controlling Interest	-	-	-	-	-	-
Other comprehensive income for the period/year attributable to:						
To the Owners of the company	-	-	3.04	-	3.24	3.11
Non Controlling Interest	-	-	-	-	-	-
Total Comprehensive Income for the period attributable to:						
To the Owners of the company	294.88	276.03	215.58	761.26	487.73	660.80
Non Controlling Interest	-	-	-	-	-	-
XII Earnings Per Share (Rs.10 each)						
(Not annualised except for the year ended 31 March 2023)						
Basic	3.83	3.80	3.04	9.88	7.44	10.09
Diluted	3.83	3.80	3.04	9.88	7.44	10.09
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	858.50	858.50	655.17	858.50	655.17	655.17

For the quarter / Nine Month ended on 31st December, 2023 EPS is calculated based on Weighted Average Number of Shares.



Notes to Unaudited Consolidated financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter and period ended December 31st 2023:

1. The unaudited consolidated financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Holding Company') along with its subsidiaries (A. - A K S Medical & Research Centre Pvt. Ltd, B- Ramraja Multispecialty Hospital & Trauma Centre Pvt Ltd and D. Sanskar Medica India Ltd.) for the quarter and period ended December 31st, 2023, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 10th, 2023. The Statement was subjected to limited review by the statutory auditors, R. Nagpal Associates, Chartered Accountants and the review report is unmodified.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in India and it constitutes the single geographical segment.
4. The figures for the quarter December 31st 2022 represent the difference between the unaudited figures in respect of period ending December 31st 2022 year and the un-audited figure of six month ended September 30th 2022.
5. The Holding Company made pre-IPO allotment of 40,00,00- shares on July 6th 2023. The Holding Company also made public offer of 2,28,85,023 shares (including 65,51,690 shares under 'Offer for Sale' by existing shareholders). All the shares under pre-IPO and public offer were made at Rs 300/share (including the premium of Rs 290/share). The Holding Company completed all the listing formalities and got the listing permission from NSE and BSE. The shares of the Holding Company started trading from August 7th, 2023. The utilization of the initial public offer proceeds is summarized below:

(in Rs. Million)

S. No	Objects of the Issue as per Prospectus	Utilization Planned as per Prospectus *	Total utilized upto 31 December, 2023	Amount pending for utilization as at 31 December 2023
1	Investment in the form of debt or Repayment/prepayment of the borrowings in full or in part of the Company, wholly owned subsidiaries, AKS and Ramraja.	2450.00	2427.19	22.81



2	Funding capital expenditure, expenses of two hospitals of the company and its namely subsidiaries; AKS and Ramraja for respective hospital operated by them.	1326.10	285.81	1040.29
3	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	-	650.00
4	General Corporate Purposes	1271.00	402.31	868.69

*Net of share issue expenses of Rs. 402.90 Million

The above-mentioned unutilized proceeds have been temporarily invested in deposits with banks.

6. Other income for the nine months period ended on 31st December, 2023 is much higher than that for Financial Year 2022-23 on account of issue proceeds being kept in fixed deposits till the time of their utilization.
7. The Company has entered into a definitive agreement with M/s Pristine Infracon Pvt. Ltd. (acquiree) and its shareholders to acquire a hospital in the city of Faridabad by way of 100% equity purchase from the existing shareholder at an overall value of Rs 116 crore. However, the right of refusal lies with the purchaser during the due diligence process.
8. The aforesaid Statement is available on the Holding Company's website (www.yatharthhospitals.in) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

On behalf of the Board of Directors

Yatharth Hospital & Trauma Care Services Ltd.

Dr. Ajay Kumar Tyagi

Designation: Chairman and Whole time Director

Place: Noida

Dated: 10/02/2023





R. NAGPAL ASSOCIATES
CHARTERED ACCOUNTANTS

B-1/1018, VASANT KUNJ,
NEW DELHI - 110 070
TELEPHONE : 011-41082626
EMAIL : rohit_mehra@rnaca.in
rnaca1@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Yatharth Hospital & Trauma Care Services Limited pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of
Yatharth Hospital & Trauma Care Services Limited**


1. We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Company) for the quarter ended December 31, 2023 and year to date from April 1, 2023 to December 31, 2023 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of



India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

For R. Nagpal Associates
Chartered Accountants
Firm Registration No. 002626N



(CA. Rohit Mehra)

Partner

Membership No. 093910



UDIN: 24093910BKAKCG2062

Place: Noida

Date: 10th February, 2024

YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: www.yatharthhospitals.com

Email: cs@yatharthhospitals.com

CIN : U85110DL2008PLC174706

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTH ENDED 31ST DECEMBER, 2023

Rs. in Million except Shares and EPS

Particulars	Standalone					
	Quarter Ended			Nine Month Ended		Year Ended
	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue from operations	1,017.31	1,101.23	970.08	3,141.97	2,743.87	3,715.14
II Other income	47.54	33.46	5.17	84.97	12.45	15.95
III Total Income (I+II)	1,064.85	1,134.69	975.26	3,226.94	2,756.32	3,731.08
IV Expenses						
Medical consumables and pharmacy items consumed	173.58	224.56	147.83	584.41	466.96	624.32
Employee benefits expense	188.94	179.06	154.69	535.68	450.57	604.53
Finance costs	1.30	15.66	26.42	41.19	63.68	87.37
Depreciation and amortisation	39.73	31.66	32.93	102.98	88.92	126.45
Other expenses	361.47	384.69	390.89	1,124.73	1,050.84	1,433.21
Total expenses (IV)	765.02	835.63	752.76	2,388.99	2,120.97	2,875.88
V Profit / (loss) before exceptional items and tax (III-IV)	299.83	299.06	222.50	837.95	635.35	855.21
VI Exceptional items (net)(Gain)/Loss	-	-	-	-	-	-
VII Profit / (loss) before tax (V-VI)	299.83	299.06	222.50	837.95	635.35	855.21
VIII Tax expense						
(1) Current tax	96.44	95.79	32.42	267.76	152.85	219.42
(2) MAT credit entitlement	-	-	-	-	-	-
(2) Income tax of earlier years	-	-	-	-	1.15	1.15
(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-	-	-
(4) Deferred tax	(7.64)	(7.17)	(6.72)	(7.35)	(7.10)	(7.10)
Total tax (VIII)	88.80	88.62	25.70	260.41	146.89	213.47
IX Net Profit/(loss) after tax (VII-VIII)	211.03	210.45	196.80	577.54	488.45	641.74
X Other Comprehensive Income						
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	3.91	-	3.05	3.05
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(0.87)	-	(0.62)	(0.62)
Other comprehensive income for the period	-	-	3.04	-	2.43	2.43
XI Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)	211.03	210.45	199.84	577.54	490.88	644.17
Profit/(Loss) for the year attributable to:						
To the Owners of the company	211.03	210.45	196.80	577.54	488.45	641.74
Non Controlling Interest	-	-	-	-	-	-
Other comprehensive income for the period/year attributable to:						
To the Owners of the company	-	-	3.04	-	2.43	2.43
Non Controlling Interest	-	-	-	-	-	-
Total Comprehensive Income for the period attributable to:						
To the Owners of the company	211.03	210.45	199.84	577.54	490.88	644.17
Non Controlling Interest	-	-	-	-	-	-
XII Earnings Per Share (Rs.10 each)						
(Not annualised except for the year ended 31 March 2023)						
Basic	2.74	2.90	3.05	7.49	7.49	9.83
Diluted	2.74	2.90	3.05	7.49	7.49	9.83
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	858.50	858.50	655.17	858.50	655.17	655.17

For the quarter/ Nine Month ended on 31st December, 2023 EPS is calculated based on Weighted Average Number of Shares.



Notes to Unaudited Standalone financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter and period ended December 31st 2023:

1. The unaudited standalone financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Company') for the quarter and period ended December 31st, 2023, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 10th, 2023. The Statement was subjected to limited review by the statutory auditors, R. Nagpal Associates, Chartered Accountants and the review report is unmodified.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Company's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The Company operates in India and it constitutes the single geographical segment.
4. The figures for the quarter December 31st 2022 represent the difference between the unaudited figures in respect of period ending December 31st 2022 year and the unaudited figure of six month ended September 30th 2022.
5. The Company made pre-IPO allotment of 40,00,00- shares on July 6th 2023. The Company also made public offer of 2,28,85,023 shares (including 65,51,690 shares under 'Offer for Sale' by existing shareholders). All the shares under pre-IPO and public offer were made at Rs 300/share (including the premium of Rs 290/share). The Company completed all the listing formalities and got the listing permission from NSE and BSE. The shares of the Company started trading from August 7th, 2023.

The utilization of the initial public offer proceeds is summarized below:

(in Rs. Million)

S. No	Objects of the Issue as per Prospectus	Utilization Planned as per Prospectus *	Total utilized upto 31 December, 2023	Amount pending for utilization as at 31 December 2023
1	Investment in the form of debt or Repayment/prepayment of the borrowings in full or in part of the Company, wholly owned subsidiaries, AKS and Ramraja.	2450.00	2427.19	22.81




2	Funding capital expenditure, expenses of two hospitals of the company and its namely subsidiaries; AKS and Ramraja for respective hospital operated by them.	1326.10	285.81	1040.29
3	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	-	650.00
4	General Corporate Purposes	1271.00	402.31	868.69

*Net of share issue expenses of Rs. 402.90 Million

The above-mentioned unutilized proceeds have been temporarily invested in deposits with banks

6. Other income for the nine months period ended on 31st December, 2023 is much higher than that for Financial Year 2022-23 on account of issue proceeds being kept in fixed deposits till the time of their utilization.
7. The Company has entered into a definitive agreement with M/s Pristine Infracon Pvt. Ltd. (acquiree) and its shareholders to acquire a hospital in the city of Faridabad by way of 100% equity purchase from the existing shareholder at an overall value of Rs 116 crore. However, the right of refusal lies with the purchaser during the due diligence process.
8. The aforesaid Statement is available on the Company's website (www.yatharthhospitals.in) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com)

On behalf of the Board of Directors
Yatharth Hospital & Trauma Care Services Ltd.


Dr. Ajay Kumar Tyagi
Designation: Chairman and Whole time Director

Place: Noida

Dated: 10/02/2023

